Newsletter

GALACTIC-HF shows that investigational agent omecamtiv mecarbil works best in heart failure patients with markedly reduced ejection fraction

American Heart Association releases new scientific statement on obesity and cardiovascular disease

Findings from the LOOK AHEAD study indicated that dyslipidemia was associated with a higher risk of CVD outcomes in large samples of obese individuals with T2DM

Entresto, a combination of sacubitril and valsartan, has been FDA approved to directly treat patients with heart failure (HF) with preserved ejection fraction (HFpEF)

Heart failure drug Vericiguat, an orally administered soluble guanylate cyclase (sGC) simulator, receives FDA approval

Happy New Year from the CMHC Team

Polypill with or without Aspirin in Persons without Cardiovascular Disease

FDA approves remdesivir as the first antiviral agent for COVID-19

Drug-Induced Arrhythmias: A Scientific Statement from the American Heart Association

Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era

Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors

Research review article highlights the status of diabetes and its complications in Latin American population

FDA approves new treatment for HFrEF

New Recommendations for Diabetes Management & Other Hormone Disorders During COVID-19 Pandemic

Hydroxychloroquine-Azithromycin Treatment For COVID-19 May Pose a Risk for Ventricular Arrhythmia

FDA Approves Two Formulations of Bempedoic Acid for LDL-C Reduction

AHA Releases 2020 Heart Disease & Stroke Statistics Update

ADA Releases 2020 Standards of Medical Care in Diabetes

DAPA-HF Study Illustrates Safety and Efficacy of Dapagliflozin In Heart Failure

FDA Approves Dapagliflozin for Heart Failure in Type 2 Diabetes

FDA Expands Recall of Common Blood Pressure Drug

Type 2 Diabetes and Cardiac Remodeling

Study finds no link between SGLT-2 inhibitors and fracture risk in patients with type 2 diabetes

FDA Panel Leans Against Eliminating PAD Device Access

Weight Loss With Metformin Maintained at 15 Years

Harmful Medications Prescribed to Nearly 25% of Patients with HFrEF

REDUCE-IT Trial Presents Updated Findings

ACC & AHA will release comprehensive guidelines for primary CVD prevention at ACC conference

SCIENTIFIC SPOTLIGHT

Role of Real-World Data on Treatment of T2DM

NEWEST PROJECT

Prior Authorization for Access Resource Center

MOMENT WITH A MEMBER

Keith C. Ferdinand, MD, FACC, FAHA

BOSTON HIGHLIGHTS

Read Press Release

CLINICALLY CURRENT CME

Access Your Online Education

SCIENTIFIC SPOTLIGHT

Meta-Analysis Reports Aggressive LDL-C Lowering Reduces Cardiovascular Risk

EVENT ANNOUNCEMENTS

Small Group Workshops

POPULAR PODCAST

Joel Kahn, MD

CLINICAL CASE CHALLENGE

Test Your Knowledge

Faculty Forum

CMHC faculty member Stephen Devries, MD

Best Blog

Fasting Diets Reduce Risk Factors For CVD

Upcoming Projects

The Cardiometabolic Chronicle

Featured Article

The Reality of Women and Cardiometabolic Disease